Novel therapies for patients with chronic myeloid leukemia

Francis J. Giles, Hagop Kantarjian, Jorge Cortes

Research output: Contribution to journalReview article

4 Scopus citations

Abstract

The most immediate issues that will have a major impact on the long-term survival of patients with chronic myeloid leukemia is the optimal use of imatinib mesylate (Gleevec®, Novartis) and the development of effective therapies for those patients who are intolerant of, or become resistant to, optimal doses of this agent. Of the multiple new agents that are currently being developed for patients with chronic myeloid leukemia, most are being investigated in patients who have developed resistance to imatinib, which is a confounding factor in itself. The mechanisms of action of novel agents are diverse and they may have a variably synergistic therapeutic relationship with imatinib. The complete blockade of the intracellular pathways that are triggered by Bcr-Abl, combined with successful reversal of apoptotic and/or angiogenic abnormalities in chronic myeloid leukemia, may well lead to a cure for the majority of patients.

Original languageEnglish (US)
Pages (from-to)271-282
Number of pages12
JournalExpert Review of Anticancer Therapy
Volume4
Issue number2
DOIs
StatePublished - Apr 2004
Externally publishedYes

Keywords

  • Chronic myeloid leukemia
  • Decitabine
  • FLT3
  • Histone deacetylase inhibitors
  • Imatinib
  • mTOR
  • Troxacitabine
  • VEGF

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Novel therapies for patients with chronic myeloid leukemia'. Together they form a unique fingerprint.

  • Cite this